Our blog

Microscope image

Our dedicated blog showcases how we translate research from the lab bench to the bedside through stories from our scientists, dealmakers, and policy influencers.

GambitBio: empowering early detection at home

A woman giving a presentation at the Bayes Centre, Edinburgh

18 June 2024
GambitBio is developing an at-home lateral flow test to screen for the most common cancers, empowering people to take control of their health and reduce the number of cancer-related deaths. We spoke to its co-founder Tiffany Ma about her journey so far.

Read more

PentaBind: revolutionising drug discovery with AI-enhanced aptamers

Three men sitting in a restaurant with their arms around each other's shoulders

13 June 2024
TechBio company PentaBind is using generative AI to develop aptamers that could target previously undruggable human proteins. We spoke to CEO and co-founder Rory Ryan about its journey.

Read more

On the horizon: exploring investment trends

Two men in shirts and jackets

11 June 2024
Genghis Lloyd-Harris, Senior Advisor at life sciences investment firm Abingworth, and Jonathan Tobin, Partner at life science venture capital firm Brandon Capital, joined our Ventures team as investors in residence in November 2023. Our Investor and External Relations Lead, Tanya Hughes, spoke to them about the current market and how their new roles will fit into it.

READ MORE

Beyond borders: going global with clinical trials

A world map

20 May 2024
There is a growing need for global collaboration on clinical trials to deliver new treatments to patients faster. Here's how international partnerships between research charities do this by pooling resources, expertise and patients. 

READ MORE

International Women's Day 2024

Jennyfer quote photo

8 March 2024
To mark #IWD24, some of our scientists tell us about their professional journeys and share advice for women embarking on a career in STEM.

READ MORE

The power of commercial data partnerships

OPTIMAM

27 February 2024
Iain Foulkes, CEO of Cancer Research Horizons, shares his thoughts on maximising the impact of patient-derived data through commercial partnerships that have clear benefits for people affected by cancer.

Read more

The UK spinout review: moving beyond equity

A photograph of the UK's Treasury offices, Horse Guards Road, London.

21 November 2023
The Government’s independent review of the UK spinout landscape reflects how well our universities commercialise their research, with some sensible suggestions on how to improve it further. Will ministers follow the recommendations or will the few loud voices urging to fix what isn’t broken drown out the data once again?

Read more

The emerging new drug class that nearly wasn’t

Scanning electron micrograph of a macrophage

4 October 2023
MOv18, the first IgE antibody to enter clinical development, exemplifies the essential nature of our non-profit research-driven organisation in bringing truly ground-breaking advances to the treatment of cancer.

Read more

The Functional Genomics Centre: building a single-cell CRISPR capability

DNA helix string

12 September 2023
The joint AstraZeneca–Cancer Research Horizons Functional Genomics Centre is collaborating with EMBL’s European Bioinformatics Institute to build its single-cell CRISPR capability. Find out how this technology advances drug discovery through genotype to phenotype correlation.

Read more

Chemistry on steroids: how we developed our expertise in steroid hydroxylation chemistry

Hydrocortisone bound to the glucocorticoid receptor

25 July 2023
Review articles on synthetic chemistry aren’t the usual output of medicinal chemists. Yet a team of Cancer Research Horizons medicinal chemists have come to write a review on the hydroxylation of steroids, detailing discoveries in the beautiful and complicatedly chiral world of steroid chemistry.

Read more

The DETERMINE trial: showcasing Cancer Research UK’s unique position in the pharma industry

DETERMINE logo

19 July 2023
Cancers that are diagnosed in fewer than 6 in 100,000 people each year are considered rare. Taken together, however, they account for 22% of all cancers diagnosed worldwide, more than any single type. Despite this, there are still far fewer treatments available for people with rare cancers. The DETERMINE trial aims to address that. 

Read more